echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > BeiGene ``Zebutinib Capsules'' New Indication Approved

    BeiGene ``Zebutinib Capsules'' New Indication Approved

    • Last Update: 2021-06-28
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    BeiGene announced that the new adaptation of Zebutinib Capsules (Baiyueze) has received conditional approval from the National Medical Products Administration
    .


    It is used to treat adult patients with Waldenstrom's macroglobulinemia (WM).


    BeiGene Official Account

    Waldenstrom's macroglobulinemia is a rare indolent lymphoma that accounts for less than 2% of non-Hodgkin's lymphoma (NHL) patients
    .


    The disease usually occurs in elderly patients and is mainly found in the bone marrow, but it may also involve the lymph nodes and spleen


    The NMPA conditional approval of Baiyueze for the treatment of WM patients who have received at least one treatment in the past is based on the safety and efficacy results of a key single-arm phase II clinical trial (NCT03332173)
    .


    The trial’s median follow-up time was 14.


    So far, Baiyueze has been approved for the following indications in the following areas:

    So far, Baiyueze has been approved for the following indications in the following areas:

    In November 2019, Baiyueze® was approved in the United States for the treatment of mantle cell lymphoma (MCL) patients who have received at least one treatment in the past*

    In June 2020, Baiyueze® was approved in China for the treatment of adult mantle cell lymphoma (MCL) patients who have received at least one treatment in the past**

    In June 2020, Baiyueze® was approved in China for the treatment of adult patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) who have received at least one treatment in the past

    In June 2021, Baiyueze® was approved in China for the treatment of adult patients with Waldenstrom's macroglobulinemia (WM) who had received at least one treatment in the past**

    In February 2021, Baiyueze® was approved in the United Arab Emirates for the treatment of patients with relapsed or refractory MCL

    In March 2021, Baiyueze® was approved in Canada for the treatment of adult patients with Waldenstrom's macroglobulinemia (WM)

    *Indicates that the indication is approved for accelerated approval based on the overall response rate (ORR)
    .


    Full approval for this indication will depend on the verification and description of clinical benefits in confirmatory trials


    **This item means that the indication has been conditionally approved
    .


    Full approval for this indication will depend on the results of ongoing confirmatory randomized, controlled clinical trials


    At present, in addition to the United States and China, a total of more than 30 Baiyueze related listing applications for multiple indications have been submitted and submitted, covering the European Union and more than 20 other countries
    .


    According to BeiGene's financial report, Baiyueze's global sales in 2020 were US$41.


    Note: The original text has been deleted

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Related Articles

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.